Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02036970 · ClinicalTrials.gov registry record · Phase 2
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
A Phase 2 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 2
- Development phase
- 166
- Enrollment target
NCT02036970 is a Phase 2 study that has completed, run by Biogen. The registered enrollment target is 166 participants.
The verdict
NCT02036970, a Phase 2 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 166 participants
- Enrollment target
Study Summary
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance (6MWD) and determine the effect of Bardoxolone methyl in pulmonary hypertension associated with connective tissue disease, interstitial lung disease, and idiopathic etiologies, including subsets of patients with WHO Group III or WHO Group V PH following 16 weeks of study participation.
Interventions
- DRUG Placebo
- DRUG Bardoxolone methyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2014-05-31 |
| Est. Completion | 2018-05-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02036970
The ClinicalTrials.gov registry entry for NCT02036970 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02036970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02036970 about?
NCT02036970 is a clinical study titled "Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT". This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance (6MWD) and determine the effect of Bardoxolone methyl in pulmonary hypert...
What is the current status of trial NCT02036970?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 166 participants. The study started on 2014-05-31. Estimated completion is 2018-05-16.
What interventions are being tested in trial NCT02036970?
The interventions under investigation include: Placebo (DRUG), Bardoxolone methyl (DRUG).
Who is sponsoring clinical trial NCT02036970?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.